Profit Motives in Vaccine Development

This chapter examines the financial gains made by vaccine manufacturers like Pfizer and Moderna amidst the pandemic, highlighting government involvement and emerging conflicts of interest. It questions the competitive landscape of public health decisions, considering the exclusion of alternative medications and the implications of emergency use authorization. The discussion reveals concerns over the motivations behind labeling mRNA technology as a vaccine and the potential consequences for public perception and health protocols.